BRAIN Biotech AG (BNN.DE)
EUR 3.77
(-3.58%)
EUR 3.77
(-3.58%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 24.94 Million EUR | 3.99% |
| 2022 | 34.33 Million EUR | 16.78% |
| 2021 | 29.4 Million EUR | 0.74% |
| 2020 | 29.18 Million EUR | 9.05% |
| 2019 | 26.76 Million EUR | 14.22% |
| 2018 | 23.43 Million EUR | 5.91% |
| 2017 | 22.12 Million EUR | -12.95% |
| 2016 | 25.41 Million EUR | 65.84% |
| 2015 | 15.32 Million EUR | 18.09% |
| 2014 | 12.97 Million EUR | 26.89% |
| 2013 | 10.22 Million EUR | 11.43% |
| 2012 | 9.17 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 9.34 Million EUR | 92.82% |
| 2024 Q1 | 9.32 Million EUR | 12.95% |
| 2024 Q2 | 4.78 Million EUR | -48.74% |
| 2023 Q1 | 9.11 Million EUR | -0.03% |
| 2023 Q4 | 8.25 Million EUR | -10.0% |
| 2023 FY | 35.7 Million EUR | 3.99% |
| 2023 Q3 | 9.17 Million EUR | 0.2% |
| 2023 Q2 | 9.15 Million EUR | 0.41% |
| 2022 Q2 | 8.84 Million EUR | 15.03% |
| 2022 FY | 34.33 Million EUR | 16.78% |
| 2022 Q4 | 9.12 Million EUR | 4.97% |
| 2022 Q3 | 8.68 Million EUR | -1.71% |
| 2022 Q1 | 7.68 Million EUR | 4.83% |
| 2021 Q1 | 6.81 Million EUR | -17.07% |
| 2021 FY | 29.4 Million EUR | 0.74% |
| 2021 Q2 | 7.66 Million EUR | 12.44% |
| 2021 Q4 | 7.33 Million EUR | -3.4% |
| 2021 Q3 | 7.58 Million EUR | -0.99% |
| 2020 Q4 | 8.22 Million EUR | 23.39% |
| 2020 Q1 | 7.21 Million EUR | 56.4% |
| 2020 Q3 | 6.66 Million EUR | -6.1% |
| 2020 Q2 | 7.09 Million EUR | -1.6% |
| 2020 FY | 29.18 Million EUR | 9.05% |
| 2019 FY | 26.76 Million EUR | 14.22% |
| 2019 Q4 | 4.61 Million EUR | -45.71% |
| 2019 Q3 | 8.49 Million EUR | 23.06% |
| 2019 Q1 | 6.76 Million EUR | -3.48% |
| 2019 Q2 | 6.9 Million EUR | 2.01% |
| 2018 Q2 | 5.36 Million EUR | 7.6% |
| 2018 FY | 23.43 Million EUR | 5.91% |
| 2018 Q4 | 7 Million EUR | 15.49% |
| 2018 Q3 | 6.06 Million EUR | 13.04% |
| 2018 Q1 | 4.98 Million EUR | 7.2% |
| 2017 Q3 | 4.65 Million EUR | -7.62% |
| 2017 Q1 | 7.77 Million EUR | -19.92% |
| 2017 Q2 | 5.04 Million EUR | -35.15% |
| 2017 FY | 22.12 Million EUR | -12.95% |
| 2017 Q4 | 4.65 Million EUR | -0.06% |
| 2016 Q4 | 9.7 Million EUR | 84.81% |
| 2016 FY | 25.41 Million EUR | 65.84% |
| 2016 Q3 | 5.25 Million EUR | -6.8% |
| 2016 Q2 | 5.63 Million EUR | 18.09% |
| 2016 Q1 | 4.77 Million EUR | 63.06% |
| 2015 Q1 | 3.64 Million EUR | 0.0% |
| 2015 FY | 15.32 Million EUR | 18.09% |
| 2015 Q2 | 4.23 Million EUR | 16.12% |
| 2015 Q3 | 4.52 Million EUR | 6.9% |
| 2015 Q4 | 2.92 Million EUR | -35.3% |
| 2014 FY | 12.97 Million EUR | 26.89% |
| 2013 FY | 10.22 Million EUR | 11.43% |
| 2012 FY | 9.17 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| BioNTech SE | 2.52 Billion EUR | 99.014% |
| CureVac N.V. | 211.75 Million EUR | 88.222% |
| Biotest Aktiengesellschaft | 136.8 Million EUR | 81.768% |
| Biotest Aktiengesellschaft | 136.8 Million EUR | 81.768% |
| Formycon AG | 23.73 Million EUR | -5.09% |
| Heidelberg Pharma AG | 27.81 Million EUR | 10.335% |
| Medigene AG | 20.54 Million EUR | -21.426% |